Lineage-and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease

Gene Therapy

Volumn 18, Issue 11, 2011, Pages 1087-1097

  Barde, I ^a   Laurenti, E ^a,d   Verp, S ^a   Wiznerowicz, M ^a,e   Offner, S ^a   Viornery, A ^b   Galy, A ^b   Trumpp, A ^c   Trono, D ^a  

^a EPFL   (Switzerland)

^b GÉNÉTHON   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Heidelberg Institute for Stem Cell Technologies and Experimental Medicine ^*  (Canada)

^e GREATER POLAND CANCER CENTER   (Poland)

Author keywords

CGD; lentiviral vector; tissue specific promoter; transcriptional targeting

Indexed keywords

CD11B ANTIGEN; CD133 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL LINEAGE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; DNA MODIFICATION; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; GENE INSERTION; GENE MUTATION; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTES; GRANULOMATOUS DISEASE, CHRONIC; LENTIVIRUS; MICE; NADPH OXIDASE; RECEPTORS, IMMUNOLOGIC;

ANIMALIA; MUS;

EID: 80855132872     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.65     Document Type: Article

References (33)

1. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419. (Pubitemid 37296260)
2. Winkelstein JA, Marino MC, Johnston Jr RB, Boyle J, Curnutte J, Gallin JI et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-169. (Pubitemid 30327530)
3. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
4. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
5. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813. (Pubitemid 34493974)
6. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
7. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
8. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 2007; 14: 337-342. (Pubitemid 46842807)
9. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.
10. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
11. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696. (Pubitemid 43882120)
12. Skalnik DG, Dorfman DM, Perkins AS, Jenkins NA, Copeland NG, Orkin SH. Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies. Proc Natl Acad Sci USA 1991; 88: 8505-8509. (Pubitemid 21915385)
13. Asante EA, Gowland I, Linehan JM, Mahal SP, Collinge J. Expression pattern of a mini human PrP gene promoter in transgenic mice. Neurobiol Dis 2002; 10: 1-7. (Pubitemid 34757076)
14. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11: 3070-3074. (Pubitemid 21895693)
15. He W, Qiang M, Ma W, Valente AJ, Quinones MP, Wang W et al. Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 2006; 17: 949-959. (Pubitemid 46076755)
16. Ramezani A, Hawley TS, Hawley RG. Performance-and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003; 101: 4717-4724. (Pubitemid 36857727)
17. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 2002; 99: 6883-6888. (Pubitemid 34526227)
18. Sauvain MO, Dorr AP, Stevenson B, Quazzola A, Naef F, Wiznerowicz M et al. Genotypic features of lentivirus transgenic mice. J Virol 2008; 82: 7111-7119. (Pubitemid 351977729)
19. Volkman DJ, Buescher ES, Gallin JI, Fauci AS. B cell lines as models for inherited phagocytic diseases: abnormal superoxide generation in chronic granulomatous disease and giant granules in Chediak-Higashi syndrome. J Immunol 1984; 133: 3006-3009. (Pubitemid 15216495)
20. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9: 202-209.
21. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995; 178: 89-97.
22. Malech HL. Progress in gene therapy for chronic granulomatous disease. J Infect Dis 1999; 179(Suppl 2): S318-S325.
23. Maly FE, Nakamura M, Gauchat JF, Urwyler A, Walker C, Dahinden CA et al. Superoxidedependent nitroblue tetrazoliumreduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines. J Immunol 1989; 142: 1260-1267. (Pubitemid 19067498)
24. Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011; 19: 122-132.
25. Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009; 17: 1537-1547.
26. Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M et al. Resistance of mature T cells to oncogene transformation. Blood 2008; 112: 2278-2286.
27. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
28. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822. (Pubitemid 34832606)
29. Grebe M, Gadea J, Steinmann T, Kientz M, Rahfeld JU, Salchert K et al. A conserved domain of the Arabidopsis GNOM protein mediates subunit interaction and cyclophilin binding. Plant Cell 2000; 12: 343-356. (Pubitemid 30186304)
30. Charrier S, Dupre L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Therapy 2007; 14: 415-428.
31. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
32. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Therapy 2005; 12: 597-606. (Pubitemid 40468107)
33. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissuespecific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872. (Pubitemid 34118370)